QQ客服 官方微博 反馈留言

浏览/检索结果: 共10条，第1-10条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Efficacy and safety of radiotherapy combined with raltitrexed and irinotecan for treating unresectable recurrent colorectal cancer: a single-arm phase II trial 期刊论文 JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022 作者:  Li, Xinghui;  Shen, Jinwen;  Xia, Fan;  Zhu, Ji 收藏  |  浏览/下载：12/0  |  提交时间：2022/12/23 Colorectal cancer  local recurrence  intensity-modulated radiotherapy  irinotecan  raltitrexed   CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial 期刊论文 CANCER COMMUNICATIONS, 2019, 卷号: 39 作者:  Shi, Yuankai;  Li, Jin;  Xu, Jianming;  Sun, Yan;  Wang, Liwei 收藏  |  浏览/下载：112/0  |  提交时间：2019/12/05 CMAB009  Cetuximab  Irinotecan  Second-line  mCRC  EGFR  KRAS  Immunogenicity  Fluoropyrimidine  Oxaliplatin failure   CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase I 期刊论文 2019, 卷号: 39, 期号: 1, 页码: 28 作者:  Shi, Yuankai;  Li, Jin;  Xu, Jianming;  Sun, Yan;  Wang, Liwei 收藏  |  浏览/下载：43/0  |  提交时间：2020/01/03 CMAB009  Cetuximab  Irinotecan  Second-line  mCRC  EGFR  KRAS  Immunogenicity  Fluoropyrimidine  Oxaliplatin failure   A phase III trial (ZJBIO009): CMAB009 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients 期刊论文 Journal of Clinical Oncology, 2017, 卷号: 35 作者:  Shi Y., Li J., Xu J., Cheng Y., Liu W., Cheng Y., Bai L., Zhang Y., He X., Luo Y., Liu Y., Yao Q., Li Y., Qin S., Hu X., Guo Y., Sun Y. 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/05 A phase III trial (ZJBI0009): CMABOO9 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients. 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2017-05-20 作者:  Shi, Yuankai;  Li, Jin;  Xu, Jianming;  Cheng, Ying;  Liu, Wei 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/04 A phase III trial (ZJBI0009): CMABOO9 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients. 期刊论文 2017, 卷号: 35 作者:   收藏  |  浏览/下载：2/0  |  提交时间：2020/01/04 Efficacy and safety evaluation of gemcitabine combined with oxaliplatin in lymphoma patients after failure of multiple chemotherapy regimens 期刊论文 2014, 卷号: 36, 期号: 2, 页码: 137-40 作者:  Yang Jianliang;  Shi Yuankai;  He Xiaohui;  Zhou Shengyu;  Dong Mei 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/13 Phase 2 Trial of Preoperative Chemoradiation Therapy With Oxaliplatin and Capecitabine for 137 Patients With Locally Advanced Rectal Carcinoma: Outcome and Failure Pattern 会议论文 INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014-09-01 作者:  Xiao, Q.;  Jin, J.;  Li, Y.;  Wang, W.;  Wang, S. 收藏  |  浏览/下载：1/0  |  提交时间：2020/01/13 Phase 2 Trial of Preoperative Chemoradiation Therapy With Oxaliplatin and Capecitabine for 137 Patients With Locally Advanced Rectal Carcinoma: Outcome and Failure Pattern 期刊论文 2014, 卷号: 90, 页码: S391-S392 作者:  Xiao, Q.;  Jin, J.;  Li, Y.;  Wang, W.;  Wang, S. 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/13 Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study 期刊论文 WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 卷号: 17 - 收藏  |  浏览/下载：6/0  |  提交时间：2020/10/26 GROWTH-FACTOR-RECEPTOR  PHASE-II TRIAL  FLUOROURACIL FAILURE  1ST-LINE TREATMENT  RANDOMIZED-TRIAL  CHEMOTHERAPY  OXALIPLATIN  EXPRESSION  INFUSION  SURVIVAL  Epidermal growth factor receptor  Cetuximab  Irinotecan  Metastatic colorectal cancer  Asia